# US 2024/0002923 A1 · Methods and kits for determining the efficiency of plasma separation from whole blood

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002923 A1
- Document ID: US20240002923A1
- Status: Published application
- Kind: A1
- Application number: 18/135,424
- Filed: 2023-04-17
- Published: 2024-01-04
- Earliest claimed: 2018-02-21
- Assignees: Nucleix Ltd.
- Applicants: Nucleix Ltd.
- Inventors: Danny FRUMKIN; Adam WASSERSTROM; Revital KNIRSH
- Web page: https://patentgrep.com/patent/US20240002923A1

## CPC

- C12Q 1/686: Polymerase chain reaction [PCR]
- G01N 33/96: involving blood or serum control standard
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Q 1/6851: Quantitative amplification
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Methods and kits for determining the efficiency of plasma separation from whole blood are provided, using real-time PCR amplification of two amplicons, namely, a short amplicon of e.g. 70-150 bps and a long amplicon of e.g. 350-600 bps. The separation efficiency is determined based on the difference in amplification patterns of the two amplicons.

## Claims

### Claim 1

A method for determining the efficiency of plasma separation from whole blood, the method comprising:
(a) separating plasma from a whole blood sample to provide a plasma sample;
(b) obtaining DNA from a plasma sample;
(c) generating by PCR co-amplification:
(i) a first amplification product of 70-150 bps from a first genomic locus using a first primer pair, and
(ii) a second amplification product of at least 350 bps from a second genomic locus using a second primer pair;
(d) calculating a signal intensity for each of said first and second amplification products, wherein said first and second amplification products produce distinct signal intensity differences for plasma DNA and whole blood DNA; and
(e) determining that the plasma sample is separated with acceptable efficiencies when the difference between the signal intensities is above a predefined threshold.

### Claim 2 (depends on 1)

The method of claim 1, wherein step (c) is performed using real-time PCR.

### Claim 3 (depends on 2)

The method of claim 2, wherein the method further comprises adding fluorescent probes for specifically detecting the first and second amplification products.

### Claim 4 (depends on 3)

The method of claim 3, wherein the signal intensity is quantification cycle (Cq), and wherein the plasma sample is determined to be separated based on the difference between the Cq values (ACq) of the first and second amplification products.

### Claim 5 (depends on 4)

The method of claim 4, wherein the plasma sample is determined to be separated when the ACq (Cq(second)−Cq(first)) is above a predefined threshold ACq.

### Claim 6 (depends on 1)

The method of claim 1, wherein said first and second primer pairs are of equal efficiency.

### Claim 7 (depends on 1)

The method of claim 1, wherein the first amplification product is of 100-150 bps.

### Claim 8 (depends on 1)

The method of claim 1, wherein the second amplification product is of 350-700 bps.

### Claim 9 (depends on 1)

The method of claim 1, wherein the second amplification product is of 350-550 bps.

### Claim 10 (depends on 1)

The method of claim 1, wherein the first amplification product comprises a sequence selected from the group consisting of SEQ ID NO: 1 and SEQ ID NO: 10.

### Claim 11 (depends on 1)

The method of claim 1, wherein the first amplification product consists of the sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 10.

### Claim 12 (depends on 1)

The method of claim 1, wherein the second amplification product comprises a sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9.

### Claim 13 (depends on 1)

The method of claim 1, wherein the second amplification product consists of the sequence set forth in SEQ ID NO: 2, SEQ ID NO: 7, SEQ ID NO: S or SEQ ID NO: 9.

### Claim 14 (depends on 1)

The method of claim 1, wherein the first and second amplification products comprise sequences as set forth in SEQ ID NO: 1 and SEQ ID NO: 2, respectively.

### Claim 15 (depends on 1)

The method of claim 1, wherein the first and second amplification products consist of sequences as set forth in SEQ ID NO: 1 and SE ID NO: 2, respectively.

### Claim 16 (depends on 1)

The method of claim 1, wherein the plasma sample is derived from a human blood sample.
